CRISPR Therapeutics AG
Research CRISPR Therapeutics AG (CRSP) on Bullrun: market cap USD 5.89B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRSP
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.89B
- Financial periodQ2 2026
- RevenueUSD 10.00M
- Net income-USD 91.15M
- Free cash flow-USD 86.62M
- Gross margin-302.7%
Valuation Snapshot
latest market cap is USD 5.89B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.51M | -USD 581.60M | -USD 345.93M | -6082.1% | -6.47 | USD 347.56M | USD 0 | USD 1.92B |
| FY2024 | USD 37.31M | -USD 366.25M | -USD 144.68M | -201.7% | -4.34 | USD 298.26M | USD 223.69M | USD 1.93B |
| FY2023 | USD 371.21M | -USD 153.61M | -USD 269.85M | n/a | -1.94 | USD 389.48M | USD 238.63M | USD 1.88B |
| FY2022 | USD 1.20M | -USD 650.18M | -USD 532.93M | n/a | -8.36 | USD 211.89M | USD 242.43M | USD 1.88B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.89B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.03B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.37B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.97B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.18B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.83B | 17.1 | n/a | n/a |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CRISPR Therapeutics AG's market cap?
CRISPR Therapeutics AG's market capitalization is USD 5.89B.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.